Review Article

Volume – 1, Issue-1, 2025
Journal home Page: https://farpublisher.com/farjams/
Page: 34-39
Publication Month: Feb.2025

HIV-Associated Nephropathy in Sickle Cell Disease Patients: A Comprehensive Review

By
*Emmanuel Ifeanyi Obeagu[1] and Francisca Ifeoma Osunwanne[2]
[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe,
ORCID: 0000-0002-4538-0161
[2]Department of Nursing Science, Faculty of Health Sciences, Imo State University, Owerri, Imo State, Nigeria.

Abstract
HIV-associated nephropathy (HIVAN) is a significant cause of kidney dysfunction in HIV-infected individuals, characterized by progressive glomerular injury, proteinuria, and potentially end-stage renal disease (ESRD). When present in patients with sickle cell disease (SCD), HIVAN compounds the already existing renal challenges faced due to the vaso-occlusive nature of SCD. This review explores the pathophysiology, clinical features, diagnostic approaches, and management strategies of HIVAN in the context of SCD. It highlights the overlapping risk factors and the increased burden of kidney disease in these patients, emphasizing the importance of early detection and personalized treatment. The pathophysiology of HIVAN in SCD patients is multifactorial, involving both direct HIV-related kidney damage and the renal ischemia caused by sickle cell vaso-occlusion. The presence of both conditions accelerates kidney deterioration, with HIVAN exacerbating the renal injury caused by recurrent vaso-occlusive crises in SCD. Diagnosis is challenging due to the similarity of symptoms between sickle cell nephropathy and HIVAN, requiring a comprehensive evaluation that includes urine tests, imaging, and in some cases, renal biopsy. Differentiating between the two conditions is critical for guiding treatment strategies.

Keywords: *HIV-associated nephropathy, sickle cell disease, kidney dysfunction, renal complications, HIV management*

Introduction

HIV-associated nephropathy (HIVAN) is a severe and progressive form of kidney disease that affects individuals living with HIV. It is primarily characterized by the rapid onset of proteinuria, nephrotic syndrome, and eventual progression to end-stage renal disease (ESRD) if left untreated. HIVAN results from the direct infection of renal cells by HIV, leading to glomerular injury and renal fibrosis. The condition is most commonly observed in individuals with advanced HIV infection, particularly those with poor viral control and low CD4 counts. In patients with sickle cell disease (SCD), a genetic hematologic disorder characterized by abnormal hemoglobin, the risk of kidney complications is already heightened. When both HIV and SCD are present, managing kidney dysfunction becomes even more complex and requires a comprehensive and multi-disciplinary approach.[1-3] Sickle cell disease is a chronic disorder characterized by the abnormal sickling of red blood cells, leading to blockages in small blood vessels, particularly in organs like the kidneys. This vaso-occlusion results in periods of ischemia and chronic low-level damage to kidney tissue, contributing to sickle cell nephropathy (SCN). Over time, the recurrent kidney injury in SCD leads to progressive renal dysfunction. The addition of HIV infection complicates the situation, as HIV directly targets renal tissue and accelerates the process of fibrosis and inflammation. HIVAN exacerbates the vascular and glomerular damage already present in SCD, potentially leading to rapid deterioration in kidney function.[4-5]

The co-occurrence of HIV and SCD significantly increases the burden of kidney disease in affected individuals. HIVAN in SCD patients can cause a rapid decline in renal function, leading to proteinuria, hematuria, and edema, which may mimic or overlap with the symptoms of sickle cell nephropathy. However, the path physiology of HIVAN is distinct, involving direct viral effects on the kidney's glomerular and tubular cells. The immune activation caused by both HIV and SCD contributes to renal inflammation, fibrosis, and scarring. This combination of mechanisms increases the risk of nephrotic syndrome and ESRD, with the need for urgent intervention to prevent irreversible kidney damage.[6-7] The diagnosis of HIVAN in SCD patients is challenging due to the overlap in clinical symptoms between sickle cell nephropathy and HIV-associated kidney injury. Proteinuria, a hallmark feature of HIVAN, is also commonly seen in SCD patients with renal involvement. Additionally, both conditions can lead to hypertension, hematuria, and kidney enlargement. Given these overlapping symptoms, clinicians must use a combination of diagnostic tools to distinguish between the two forms of kidney damage. Urine tests, such as 24-hour urine protein collection, imaging studies like renal ultrasound, and biopsy procedures, if necessary, are crucial for accurate diagnosis. The renal biopsy is often the most definitive diagnostic tool for distinguishing HIVAN from other renal pathologies, although it may be difficult to perform in SCD patients due to the risk of bleeding.[8-10]

Early diagnosis of HIV-associated nephropathy in SCD patients is essential for slowing the progression of kidney disease. Once HIVAN is diagnosed, treatment typically involves the initiation of antiretroviral therapy (ART) to suppress HIV replication. ART has been shown to reduce the viral load, improve renal function, and slow the progression of kidney disease in individuals with HIVAN. However, the presence of sickle cell disease adds an

additional layer of complexity. Some ART regimens, particularly those that include protease inhibitors, have been associated with nephrotoxicity, making the selection of appropriate medications critical in this population. Nephrologists must work closely with infectious disease specialists to monitor renal function and adjust ART regimens accordingly to avoid further renal damage.[11-13] In addition to ART, other interventions are necessary to manage renal dysfunction in HIV-positive SCD patients. Blood pressure control is a key aspect of managing kidney disease in this population, as hypertension accelerates the progression of renal damage. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are commonly prescribed to reduce proteinuria and lower blood pressure, both of which are important for preserving kidney function. Maintaining hydration, optimizing hemoglobin levels, and managing sickle cell crises are equally important to prevent further kidney damage. Furthermore, regular monitoring of renal function through routine blood tests, urine protein measurements, and imaging is essential for tracking the progression of kidney disease and adjusting the treatment plan as needed.[14-16]

Pathophysiology of HIVAN in Sickle Cell Disease

HIV-associated nephropathy (HIVAN) is a complex and progressive kidney disorder that occurs in individuals infected with HIV, characterized by rapid deterioration in renal function, proteinuria, and nephrotic syndrome. The pathophysiology of HIVAN is primarily driven by direct infection of renal cells by HIV, which leads to inflammation, fibrosis, and subsequent glomerular and tubular damage. In individuals with sickle cell disease (SCD), this renal pathology is compounded by the additional burden of vaso-occlusive events, hypoxia, and ischemia, making the kidneys particularly vulnerable to both conditions simultaneously. The interaction between HIV infection and SCD exacerbates kidney dysfunction, accelerating the progression of renal disease.[17-19] In HIV-positive individuals, the virus enters renal cells through the CD4 receptor and co-receptors such as CCR5 and CXCR4, leading to direct viral replication within glomerular epithelial cells (podocytes) and renal tubular cells. This causes a cascade of inflammatory responses, including the activation of immune cells, cytokine production, and an increased deposition of extracellular matrix proteins, which collectively lead to glomerulosclerosis and tubulointerstitial fibrosis. Additionally, HIV proteins such as Tat and gp120 can exert direct cytotoxic effects on renal cells, further contributing to renal injury and dysfunction. In SCD patients, the kidney already experiences chronic damage due to recurrent vaso-occlusive crises, which result in ischemia, inflammation, and endothelial injury. The presence of both conditions creates a "two-hit" scenario, where the renal vasculature and glomeruli are not only damaged by the sickling of red blood cells but are also directly attacked by HIV.[20-22]

The renal damage in HIV-positive individuals with SCD is compounded by the fact that sickle cell disease leads to a hypercoagulable state, contributing to microvascular obstruction and hypoxia in various organs, including the kidneys. The sickling of red blood cells reduces the oxygen-carrying capacity of the blood, causing ischemic damage to renal tissue. This vaso-occlusion contributes to glomerular injury, endothelial dysfunction, and tubulointerstitial fibrosis. When combined with the effects of HIV infection, which increases renal inflammation, the progression to nephropathy becomes much faster and more severe. Additionally, chronic kidney injury in SCD patients often results in a vicious cycle of worsening anemia, impaired erythropoiesis, and kidney dysfunction, making treatment more challenging.[23-25] HIVAN in SCD patients typically manifests as proteinuria, hematuria, and hypertension, all of which are common features of kidney involvement in both conditions. Proteinuria in particular is a hallmark of HIVAN and can be a crucial early indicator of kidney damage. In SCD patients, glomerular filtration rate (GFR) decline is often more rapid, with a higher likelihood of progression to end-stage renal disease (ESRD) due to the combined renal insults from both HIV and sickle cell disease. Furthermore, HIV-induced nephropathy in this population can complicate the management of other sickle cell-related complications, such as episodes of pain crises and organ damage, making a multi-disciplinary approach essential for optimal care.[26-27]

Clinical Manifestations and Diagnosis of HIVAN in Sickle Cell Disease

The clinical manifestations of HIV-associated nephropathy (HIVAN) in patients with sickle cell disease (SCD) can be challenging to differentiate from the kidney complications already present in individuals with SCD. Both conditions share similar renal symptoms, such as proteinuria, hematuria, and hypertension, which can make early diagnosis difficult. HIVAN in SCD patients can also present with symptoms of nephrotic syndrome, including edema, hypoalbuminemia, and elevated serum cholesterol. However, the progression and underlying causes of kidney injury in HIV-positive SCD patients are multifactorial, involving both direct viral effects on the kidneys and the damage caused by recurrent sickling of red blood cells and subsequent vaso-occlusion. Early identification of HIVAN is crucial, as it can significantly accelerate kidney dysfunction and contribute to the rapid progression of end-stage renal disease (ESRD).[28-30] One of the hallmark signs of HIVAN is proteinuria, which is frequently detected during routine urinalysis. Proteinuria may range from mild to nephrotic levels, with massive protein leakage into the urine indicating more severe kidney damage. Hematuria, or the presence of blood in the urine, may also be observed in patients with HIVAN, though it is not as prominent as proteinuria. In individuals with SCD, hematuria can occur as a result of vaso-occlusion in the renal microvasculature, which leads to glomerular injury. However, when proteinuria and hematuria occur concurrently in HIV-positive SCD patients, this is a strong indicator of the potential presence of HIVAN. Hypertension is another common feature of HIVAN and is often seen in patients with kidney dysfunction in both HIV and SCD. Increased blood pressure can worsen kidney damage and, if left untreated, may lead to further renal decline.[31-32]

Diagnosing HIVAN in SCD patients requires a comprehensive evaluation that includes a thorough clinical assessment, laboratory investigations, and imaging studies.

A detailed history should focus on the onset and progression of renal symptoms, including changes in urine output, the presence of edema, and any recent episodes of pain crises that may have exacerbated kidney function. Urinalysis is the first step in evaluating renal function, with proteinuria being the primary indicator of renal damage. Quantification of proteinuria through a 24-hour urine collection or urine protein-to-creatinine ratio is essential to assess the extent of kidney injury. If significant proteinuria is present, further diagnostic testing is warranted.[33-35] Imaging studies, such as renal ultrasound, are commonly used to assess kidney size, detect any structural abnormalities, and rule out other causes of renal impairment. HIVAN can cause renal enlargement due to inflammation and glomerular hyperplasia, which may be evident on ultrasound. However, imaging alone cannot definitively distinguish between HIVAN and sickle cell nephropathy, which may also present with similar findings, such as renal enlargement and scarring. In some cases, a renal biopsy may be necessary to provide a more definitive diagnosis. A biopsy can help differentiate between HIVAN and other causes of renal damage, such as sickle cell nephropathy, by examining the histopathological features of the kidney tissue. In HIVAN, the biopsy typically reveals collapsing focal segmental glomerulosclerosis (FSGS), which is a hallmark of the disease.[36-38] The diagnosis of HIVAN in SCD patients is also aided by laboratory tests to assess the presence of HIV infection and to monitor viral load, CD4 count, and kidney function. Monitoring serum creatinine levels, estimated glomerular filtration rate (eGFR), and blood urea nitrogen (BUN) helps track kidney function over time. HIV viral load suppression, indicated by a low or undetectable viral load, is an important predictor of renal disease progression. A low CD4 count, commonly seen in patients with untreated HIV, may indicate a more advanced HIV infection and a higher risk of developing HIVAN.[39-40]

Management and Treatment Strategies for HIVAN in Sickle Cell Disease

The management of HIV-associated nephropathy (HIVAN) in patients with sickle cell disease (SCD) requires a multi-disciplinary approach that addresses both the renal complications of HIV infection and the unique renal issues associated with SCD. Early recognition of HIVAN is crucial to prevent or delay the progression to end-stage renal disease (ESRD). Given the complexity of managing dual pathologies, the therapeutic strategies focus on controlling HIV replication, managing renal complications, and alleviating the effects of sickle cell disease. This requires an integrated approach that involves antiretroviral therapy (ART), supportive renal care, and targeted interventions to mitigate the complications associated with SCD.[41]

Antiretroviral Therapy (ART) is the cornerstone of HIV treatment in individuals with HIVAN. Effective viral suppression is essential in reducing the progression of kidney disease. ART regimens typically include a combination of drugs that target different stages of the HIV life cycle, such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Studies have shown that effective ART can reduce the severity of HIVAN by decreasing the viral load and preventing further kidney damage. However, caution must be exercised in choosing ART regimens for SCD patients, as some antiretroviral drugs may have nephrotoxic side effects. For example, tenofovir, an NRTI, is known to cause renal toxicity, particularly in patients with pre-existing kidney disease. Therefore, the selection of ART should be carefully monitored and adjusted according to renal function.[42-43]

Renal Protective Strategies are critical in managing HIVAN in SCD patients. The use of angiotensin-converting enzyme inhibitors **(**ACE inhibitors**)** or angiotensin II receptor blockers **(**ARBs**)** is a standard approach to reduce proteinuria, which is a hallmark of HIVAN. These medications not only reduce proteinuria but also help in controlling blood pressure, which is often elevated in patients with renal dysfunction. ACE inhibitors and ARBs are particularly effective in patients with proteinuria and hypertension, helping to protect the kidneys from further damage. Regular monitoring of kidney function, including serum creatinine, glomerular filtration rate (GFR), and urine protein levels, is essential to assess the effectiveness of these therapies and adjust the treatment plan accordingly.[44-45]

Supportive Care for sickle cell disease plays a critical role in the management of kidney disease in these patients. Frequent blood transfusions may be necessary to manage sickle cell-related anemia and prevent further sickling episodes, which can worsen kidney function. In addition, maintaining hydration is important to reduce the risk of vaso-occlusion in the kidneys, which can lead to ischemic damage and further exacerbation of kidney injury. Patients with HIVAN and SCD should also receive appropriate management for any other complications of SCD, including pain crises, infection prevention (due to compromised immunity), and stroke prophylaxis. Hydroxyurea, a medication that helps reduce the frequency of vaso-occlusive episodes, may also play a role in reducing renal injury by limiting the occurrence of sickle cell-related crises.[46]

Management of Hypertension is an essential aspect of treatment for HIVAN in SCD patients. Hypertension is common in both HIVAN and SCD and can exacerbate kidney damage. Blood pressure should be carefully monitored, and antihypertensive medications, including ACE inhibitors or ARBs, should be adjusted to maintain blood pressure within optimal ranges. In some cases, calcium channel blockers or diuretics may be added to the regimen to control hypertension and reduce fluid retention, especially in patients with nephrotic syndrome. Monitoring for side effects, such as electrolyte imbalances or fluid overload, is essential, particularly in patients with compromised renal function.[47] **Renal Replacement Therapy (RRT)**, including hemodialysis or peritoneal dialysis, may become necessary for patients with advanced HIVAN in SCD who progress to ESRD. The decision to initiate dialysis should be based on the patient's overall clinical condition, GFR, and other relevant factors such as comorbidities. Kidney transplantation is another potential treatment option, but it may be complicated by the presence of HIV, requiring careful consideration of immunosuppressive therapy and HIV viral load control.[48]

Conclusion

HIV-associated nephropathy (HIVAN) in sickle cell disease (SCD) patients presents a complex and multifactorial challenge, requiring careful management to prevent rapid progression to end-stage renal disease (ESRD). The interplay between the two conditions—HIV and sickle cell disease—exacerbates renal dysfunction, making early diagnosis and intervention critical. The cornerstone of managing HIVAN in SCD patients is the effective control of HIV through antiretroviral therapy (ART), which helps reduce viral load and limit kidney damage. However, ART selection must be carefully considered, as certain medications may contribute to renal toxicity, especially in those with pre-existing renal compromise. In addition to ART, renal protective strategies such as the use of ACE inhibitors or ARBs are crucial in controlling proteinuria and hypertension, which are common in HIVAN and SCD. These medications not only help reduce kidney damage but also support overall cardiovascular health. Furthermore, managing sickle cell disease-related complications through transfusions, hydration, and the use of hydroxyurea is vital to minimize the impact of sickle cell crises on renal function. A multidisciplinary approach, involving nephrologists, hematologists, and infectious disease specialists, is essential for optimizing care and improving outcomes.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV

Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo

Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40

